About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:2653501
Allelic
Composition
Gata1tm2Sho/Gata1tm2Sho
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gata1tm2Sho mutation (1 available); any Gata1 mutation (45 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• no sign of active hemopoiesis is seen in the liver of mutants after birth (1-12 months of age), however by 18 months of age, foci of hematopoiesis are seen in the liver parenchyma
• number of myeloid progenitor cells (CFU-GM) circulating in the blood increases by 2- to 10-fold at 8-12 months of age and remain higher than normal after this time (J:78348)
• spleen and marrow contains increased numbers of megakaryocytic and bipotent (erythroid/megakaryocytic) precursors (J:78540)
• transition of the major hematopoietic site from the marrow to the spleen
• mutants become anemic from 15 months of age
• total marrow cellularity is reduced already at 4-8 months of age and further reduced by 2-fold at 15-20 months of age (J:78348)
• 2- to 3-fold decrease in the frequency of all types of progenitor cells in the bone marrow with age; when adjusted for the reduction in total marrow cellularity, corresponds to a 4-fold reduction in total number of progenitor cells per femur (J:78348)
• bone marrow contains 3 times fewer cells than wild-type (J:78540)
• erythroid progenitors (BFU-E, CFU-E) in the spleen, though higher than in wild-type mice, decrease 2- to 3-fold over time in mutants (J:78348)
(J:78540)
• overall erythroid precursor cell content in the marrow is lower than in wild-type
• number of erythroid progenitor cells (CFU-E and BFU-E) circulating in the blood increases by 2- to 10-fold at 8-12 months of age and remain higher than normal after this time (J:78348)
• marrow and spleen contain a higher frequency of burst-forming units-erythroid (BFU-E)- and colony-forming units-erythroid (CFU-E) derived colonies (J:78540)
• spleen contains 7-20-fold higher numbers of erythroid precursors and bipotent (erythroid/megakaryocytic) precursors (J:78540)
• phenylhydrazine (PHZ) treated mutants exhibit an increase in CFU-E (J:78540)
• erythropoietin (EPO) treated mutants exhibit an increase in both early (BFU-E) and late (CFU-E) progenitor cells in the marrow and spleen (J:78540)
• number of megakaryocyte progenitor cells (CFU-Mk) circulating in the blood increases by 18-20 months of age
• frequency of megakaryocytic progenitors (CFU-Mkp and CFU-Mkm) in the spleen, which are already higher at 4-8 months of age, further increases at 15-20 months
• however, due to the overall decrease in spleen cellularity, the total number of progenitor cells of all types in the spleen decreases with age
• number of circulating red cells is decreased at 15-20 months of age
• mutants exhibit an accelerated hematocrit response to both acute (PHZ treatment) and chronic (EPO administration) erythroid stimulation which lasts longer than in wild-type
• at 15-20 months of age
• erythrocytes with Howell-Jolly bodies are seen in the blood
• tear-drop poikilocytes are seen in the blood
• erythrocytes with polychromatophilia are seen in the blood
• progressive increase in the percentages of neutrophils by 15-20 months of age
(J:78348)
• 10-fold decrease in platelet numbers (J:78540)
• mutants are thrombocytopenic in response to phenylhydrazine (PHZ)-induced anemia or erythropoietin (EPO)-iduced polycythemia but have normal hematocrit levels (J:78540)
(J:78348)
• platelets appear abnormal and bigger than normal platelets (J:78540)
• progressive decrease in the percentage of lymphocytes
• accumulation of reticulin fibers with age in the spleen
• while spleen size further increases with age, total spleen cellularity, though remaining significantly higher than in normal mice, decreases with age; total number of cells in the spleen is first reduced at 8-12 months of age
• however, due to the overall decrease in spleen cellularity, the total number of progenitor cells of all types in the spleen decreases with age
• spleen size increases with age and at 15-20 months of age is due to an accumulation of collagen fibers (J:78348)
• spleens are 2.5-fold larger (J:78540)
• spleens of PHZ-and EPO-treated mutants are bigger and contain more cells than treated controls (J:78540)
• the interfollicular space of the red pulp is filled with abnormally large and dysplastic megakaryocytes
• red pulp and subcapsulary space are filled with lymphocyte-sized cells resembling immature erythroid cells
• spleen contains 3 times more cells than wild-type

homeostasis/metabolism
• mutants recover 2 days faster from the PHZ-induced anemia than controls

immune system
• progressive increase in the percentages of neutrophils by 15-20 months of age
• progressive decrease in the percentage of lymphocytes
• accumulation of reticulin fibers with age in the spleen
• while spleen size further increases with age, total spleen cellularity, though remaining significantly higher than in normal mice, decreases with age; total number of cells in the spleen is first reduced at 8-12 months of age
• however, due to the overall decrease in spleen cellularity, the total number of progenitor cells of all types in the spleen decreases with age
• spleen size increases with age and at 15-20 months of age is due to an accumulation of collagen fibers (J:78348)
• spleens are 2.5-fold larger (J:78540)
• spleens of PHZ-and EPO-treated mutants are bigger and contain more cells than treated controls (J:78540)
• the interfollicular space of the red pulp is filled with abnormally large and dysplastic megakaryocytes
• red pulp and subcapsulary space are filled with lymphocyte-sized cells resembling immature erythroid cells
• spleen contains 3 times more cells than wild-type

skeleton
• starting at 12 months of age, a progressive reduction of the space available in the bone marrow for hemopoietic cells due to the simultaneous increase of bone trabeculae and intracellular matrix (J:78348)
• progressive accumulation of fibers in the intercellular space of the marrow; the fibers change from fine and diffuse reticulin fibers at 6 months of age to gross collagen fibers from 12 months on and almost completely fills the femoral cavity (J:78348)
• bone marrow contains larger-than-normal red cells and apoptotic cells (J:78540)
• myelofibrotic degeneration of the marrow and spleen with age; about 7 times more megakaryocytes in the bone marrow than controls
• expression of growth factor genes implicated in the development of myelofibrosis is increased in the marrow
• presence of tear-drop poikilocytes and progenitor cells in the blood, collagen fibers in the marrow and in the spleen and hemopoietic foci in the liver, all markers of myelofibrosis
• starting at 12 months of age, an increase of bone trabeculae is seen in the bone marrow
• in the oldest mice, increased osteogenesis eventually occludes the femoral cavity

liver/biliary system
• starting from 8-12 months of age, significant numbers of progenitor cells are seen in the liver that increases further at 15-20 months of age

mortality/aging
• most mutants die between 14 and 20 months of age, and only 9 survive past 20 months of age
• 9 of 178 mutants born alive die within the first 15 days of life
• only 30% of pregnancies induced result in viable pups

growth/size/body
• spleen size increases with age and at 15-20 months of age is due to an accumulation of collagen fibers (J:78348)
• spleens are 2.5-fold larger (J:78540)
• spleens of PHZ-and EPO-treated mutants are bigger and contain more cells than treated controls (J:78540)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myelofibrosis DOID:4971 OMIM:254450
J:78348


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory